Get the Stockscreener App
2.23
18.62%
0.35
Sab Biotherapeutics Inc stock is traded at $2.23, with a volume of 258.62K.
It is up +18.62% in the last 24 hours and up +26.70% over the past month.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
See More
Previous Close:
$1.88
Open:
$1.85
24h Volume:
258.62K
Relative Volume:
0.19
Market Cap:
$20.71M
Revenue:
-
Net Income/Loss:
$-45.57M
P/E Ratio:
-0.354
EPS:
-6.3
Net Cash Flow:
$-38.56M
1W Performance:
-12.55%
1M Performance:
+26.70%
6M Performance:
+1.83%
1Y Performance:
-19.49%
1-Day Range:
$1.85
$2.3099
1-Week Range:
$1.85
$2.67
52-Week Range:
$1.00
$6.60
Sab Biotherapeutics Inc Stock (SABS) Company Profile
Name
Sab Biotherapeutics Inc
Sector
Industry
Phone
305-845-2813
Address
777 W 41ST ST, MIAMI BEACH
Compare SABS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SABS
Sab Biotherapeutics Inc
|
2.23 | 17.46M | 0 | -45.57M | -38.56M | -6.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-14-25 | Resumed | H.C. Wainwright | Buy |
| Oct-09-24 | Initiated | Craig Hallum | Buy |
| Aug-28-24 | Initiated | Oppenheimer | Outperform |
| Nov-05-21 | Initiated | Chardan Capital Markets | Buy |
Sab Biotherapeutics Inc Stock (SABS) Latest News
Will SAB Biotherapeutics Inc. stock benefit from interest rate changesShort Term Profit Strategy with Entry Cues - Newser
How volatile is SAB Biotherapeutics Inc. stock compared to the marketStock Strategy Signals For Consistent Profits - jammulinksnews.com
What institutional investors are buying SAB Biotherapeutics Inc. stockDaily Trading Target Finder That Work - jammulinksnews.com
What makes SAB Biotherapeutics Inc. stock price move sharplySmart Portfolio Growth Plan For Beginners - jammulinksnews.com
Technical analysis overview for SAB Biotherapeutics Inc. stockFree Capital Protection Trading Strategies - Newser
SAB Biotherapeutics Inc. stock retracement – recovery analysisFree Market Momentum and Signal Alerts - Newser
What are analysts’ price targets for SAB Biotherapeutics Inc. Equity Warrant in the next 12 monthsEarnings Report Alerts To Watch Now - jammulinksnews.com
Measuring SAB Biotherapeutics Inc.’s beta against major indicesHigh Return Strategy with Low Risk - Newser
Visual analytics tools that track SAB Biotherapeutics Inc. performanceFree Accurate Technical Trend Reversal Picks - Newser
Is SAB Biotherapeutics Inc. Equity Warrant stock overvalued or undervaluedMarket Forecast Review For 2025 - jammulinksnews.com
Analyzing SAB Biotherapeutics Inc. Equity Warrant with risk reward ratio chartsFree Consistent Gain Investment Strategies - Newser
How to use a screener to detect SAB Biotherapeutics Inc. breakoutsFree Stock Selection With High Accuracy - Newser
Intrinsic Value of SAB Biotherapeutics Inc. Stock: Is It Undervalued or OvervaluedDaily Market Entry Strategy with Tools - Newser
Should you hold or exit SAB Biotherapeutics Inc. Equity Warrant nowFree Low Risk Swing Trade Opportunity List - Newser
Predicting SAB Biotherapeutics Inc. Equity Warrant trend using moving averagesEntry and Exit Strategy for Swing Traders - Newser
SAB Biotherapeutics Inc. Approaches Support With Recovery in SightAI Based High Gain Watchlist Scanner Shared - metal.it
What makes SAB Biotherapeutics Inc. Equity Warrant stock price move sharplyStrategy Playbook for Risk Controlled Trades - Newser
Exit strategy if you’re trapped in SAB Biotherapeutics Inc. Equity WarrantVolume Spike Detection for Early Breakouts - Newser
Sectors Driving Future Growth for SAB Biotherapeutics Inc. Equity Warrant StockAI-Based Signal Detection for Active Traders - Newser
What are analysts’ price targets for SAB Biotherapeutics Inc. in the next 12 monthsEntry Signal Forecasts For Consistent Profits - jammulinksnews.com
What are the latest earnings results for SAB Biotherapeutics Inc. Equity WarrantValue Investing Recommendation For Every Investor - jammulinksnews.com
SAB Biotherapeutics Inc. Charts Flash Early Recovery SignalsLow Risk Picks for Daily Trading Released - metal.it
When is SAB Biotherapeutics Inc. Equity Warrant stock expected to show significant growthWealth Building Review With Proven Results - jammulinksnews.com
Published on: 2025-07-28 18:51:18 - metal.it
What is the risk reward ratio of investing in SAB Biotherapeutics Inc. stockMaximize gains with strategic stock entries - jammulinksnews.com
What catalysts could drive SAB Biotherapeutics Inc. Equity Warrant stock higher in 2025Build wealth faster with consistent growth stocks - jammulinksnews.com
Is SAB Biotherapeutics Inc. meeting your algorithmic filter criteriaFree Daily Stock Market Swing Alerts - Newser
Why is SAB Biotherapeutics Inc. Equity Warrant stock attracting strong analyst attentionAccelerated capital growth - jammulinksnews.com
Is it the right time to buy SAB Biotherapeutics Inc. Equity Warrant stockPhenomenal wealth increase - jammulinksnews.com
What institutional investors are buying SAB Biotherapeutics Inc. Equity Warrant stockExpert guidance for superior capital growth - jammulinksnews.com
How many analysts rate SAB Biotherapeutics Inc. as a “Buy”Harness the power of proven investment plans - jammulinksnews.com
Published on: 2025-07-28 11:38:46 - metal.it
Long term hold vs stop loss in SAB Biotherapeutics Inc. Equity Warrant Market Forecast Summary Over Multi-Year Period - Newser
What are SAB Biotherapeutics Inc. company’s key revenue driversStock Market Forecasts For 2025 - jammulinksnews.com
What is the risk reward ratio of investing in SAB Biotherapeutics Inc. Equity Warrant stockInvest confidently with professional market insights - jammulinksnews.com
Why SAB Biotherapeutics Inc. Equity Warrant stock attracts strong analyst attention Free Daily Smart Money Movement Monitor - metal.it
What are the technical indicators suggesting about SAB Biotherapeutics Inc. Equity WarrantDiscover stocks with massive upside potential - jammulinksnews.com
Does SAB Biotherapeutics Inc. Equity Warrant stock perform well during market downturnsHarness the power of proven investment plans - jammulinksnews.com
How does SAB Biotherapeutics Inc. Equity Warrant generate profit in a changing economyMaximize portfolio growth with expert advice - jammulinksnews.com
Sab Biotherapeutics Inc Stock (SABS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):